STERIS (STE) Hisse Özeti
STERIS plc, Amerika Birleşik Devletleri, İrlanda ve uluslararası alanda enfeksiyon önleme ürünleri ve hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 4/6 |
STE Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STERIS plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$232.64 |
| 52 Haftanın En Yüksek Seviyesi | US$269.44 |
| 52 Haftanın En Düşük Seviyesi | US$195.14 |
| Beta | 0.91 |
| 1 Aylık Değişim | 6.62% |
| 3 Aylık Değişim | 8.48% |
| 1 Yıllık Değişim | 3.92% |
| 3 Yıllık Değişim | 3.29% |
| 5 Yıllık Değişim | 6.90% |
| Halka arzdan bu yana değişim | 11,179.52% |
Son Haberler & Güncellemeler
Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.Recent updates
Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.Anlatı Güncellemesi • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.Anlatı Güncellemesi • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.Anlatı Güncellemesi • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).Anlatı Güncellemesi • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.Anlatı Güncellemesi • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Analiz Makalesi • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...Anlatı Güncellemesi • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Anlatı Güncellemesi • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.Anlatı Güncellemesi • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.Anlatı Güncellemesi • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).Anlatı Güncellemesi • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Analiz Makalesi • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...Anlatı Güncellemesi • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).Anlatı Güncellemesi • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).Anlatı Güncellemesi • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.Anlatı Güncellemesi • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Analiz Makalesi • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Anlatı Güncellemesi • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Analiz Makalesi • Aug 28
Calculating The Fair Value Of STERIS plc (NYSE:STE)
Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...Analiz Makalesi • Aug 07
STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year
The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 16
Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
Yeni Anlatı • Aug 20
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Seeking Alpha • Aug 13
Steris: Q2 Numbers Solidify Buy Thesis
Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking AlphaHissedar Getirileri
| STE | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 1.0% | 2.3% | 2.4% |
| 1Y | 3.9% | -12.8% | 19.6% |
Getiri vs. Endüstri: STE geçen yıl % -12.8 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: STE geçen yıl % 19.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| STE volatility | |
|---|---|
| STE Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: STE son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: STE 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1985 | 17,937 | Dan Carestio | www.steris.com |
STERIS plc, Amerika Birleşik Devletleri, İrlanda ve uluslararası alanda enfeksiyon önleme ürünleri ve hizmetleri sunmaktadır. Üç segmentte faaliyet göstermektedir: Sağlık Hizmetleri, Uygulamalı Sterilizasyon Teknolojileri ve Yaşam Bilimleri. Şirket, temizlik kimyasalları ve sterilite güvence ürünleri, otomatik endoskop yeniden işleme sistemi ve izleme ürünleri, endoskopi aksesuarları, aletler, yıkayıcılar ve sterilizatörler ve diğer sermaye ekipmanlarının yanı sıra cerrahi masalar, ışıklar, ekipman yönetim hizmetleri ve bağlantı çözümleri dahil olmak üzere doğrudan prosedür odalarında kullanılan ekipmanlar sunmaktadır; ve çeşitli önleyici bakım programları, onarım hizmetleri, özel süreç iyileştirme danışmanlığı ve dış kaynaklı alet steril işlemenin yanı sıra alet, cihaz ve endoskop onarım ve bakım hizmetleri.
STERIS plc Temel Bilgiler Özeti
| STE temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$22.67b |
| Kazançlar(TTM) | US$782.30m |
| Gelir(TTM) | US$5.94b |
29.0x
F/K Oranı3.8x
P/S OranıSTE aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| STE gelir tablosu (TTM) | |
|---|---|
| Gelir | US$5.94b |
| Gelir Maliyeti | US$3.31b |
| Brüt Kâr | US$2.63b |
| Diğer Giderler | US$1.84b |
| Kazançlar | US$782.30m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 05, 2026
| Hisse başına kazanç (EPS) | 8.03 |
| Brüt Marj | 44.24% |
| Net Kâr Marjı | 13.18% |
| Borç/Özkaynak Oranı | 26.8% |
STE uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.1%
Mevcut Temettü Verimi31%
Ödeme OranıSTE güvenilir bir temettü ödüyor mu?
STE temettü geçmişine ve kıyaslamalara bakın| STERIS temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Sep 04 2026 |
| Temettü Ödeme Tarihi | Sep 25 2026 |
| Eski temettüye kadar geçen günler | 31 days |
| Temettü ödeme tarihine kadar geçen günler | 52 days |
STE güvenilir bir temettü ödüyor mu?
STE temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/04 11:38 |
| Gün Sonu Hisse Fiyatı | 2026/08/03 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
STERIS plc 17 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |